" class="no-js "lang="en-US"> DeepSight ™ Technology Announces $25M Series A Funding Round - Medtech Alert
Thursday, February 09, 2023

DeepSight ™ Technology Announces $25M Series A Funding Round

DeepSight ™ Technology has announced a $25 million Series A led by Deerfield Management Company, a healthcare investment firm, with additional funding from Wing, Alter Venture Partners, and Time BioVentures

“We are excited to be on the frontier of advancing medical imaging,” said founder and CEO Nader Sadrzadeh. “Based on internal studies, our technology has the potential to achieve 100 times greater sensitivity, ultimately allowing us to deliver better patient care.”

DeepSight is augmenting diagnostic medical imaging with the introduction of novel ultrasound technology, using patented hardware, software, and AI algorithms to deliver 100 times higher sensitivity than other ultrasound systems in the market. Existing ultrasound technologies are limited by sensitivity, depth penetration and clarity. DeepSight improves ultrasound image quality and more than doubles the effective range when compared to conventional technologies.

“DeepSight Technology provides a potential platform opportunity to enhance non-invasive and invasive medical imaging for multiple diagnostic procedures, and in turn, improve the patient care process with more efficacious testing that costs less,” said Steven Hochberg, Partner at Deerfield. “We are pleased to be leading this Series A financing in a novel medical device technology which has the potential to help advance a range of imaging procedures.” 

People In This Post

Companies In This Post

  1. ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Read more
  2. Superior HealthPlan and eFamilyCare Expand Partnership to Support Medicaid Members and Caregivers in Texas Read more
  3. Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform Read more
  4. FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate Read more
  5. $25 Million Gift to Penn Medicine and Children’s Hospital of Philadelphia Establishes Center for Epilepsy and Neurodevelopmental Disorders Read more